Cantor Fitzgerald Weighs in on Verona Pharma FY2025 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Stock analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Verona Pharma in a report released on Wednesday, April 30th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will earn $0.10 per share for the year, down from their previous estimate of $0.11. Cantor Fitzgerald currently has a "Overweight" rating and a $80.00 target price on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The firm had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million.

Several other research firms also recently commented on VRNA. HC Wainwright boosted their target price on shares of Verona Pharma from $75.00 to $85.00 and gave the stock a "buy" rating in a research report on Wednesday. Roth Capital set a $83.00 price objective on Verona Pharma in a research note on Friday, February 28th. Truist Financial reaffirmed a "buy" rating and set a $57.00 target price (up previously from $44.00) on shares of Verona Pharma in a research report on Wednesday, January 8th. Wells Fargo & Company upped their price target on Verona Pharma from $93.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Roth Mkm assumed coverage on Verona Pharma in a research note on Friday, January 10th. They set a "buy" rating and a $68.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $81.50.

Verona Pharma Stock Up 0.7 %

VRNA stock traded up $0.47 during midday trading on Thursday, reaching $72.73. 1,449,011 shares of the company's stock traded hands, compared to its average volume of 1,270,611. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $74.18. The company has a market cap of $5.88 billion, a price-to-earnings ratio of -37.88 and a beta of 0.20. The firm's fifty day moving average price is $63.10 and its 200-day moving average price is $52.02. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93.

Insider Transactions at Verona Pharma

In other news, insider Kathleen A. Rickard sold 34,384 shares of Verona Pharma stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total value of $308,768.32. Following the completion of the transaction, the insider now directly owns 2,660,656 shares in the company, valued at approximately $23,892,690.88. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vikas Sinha sold 20,000 shares of the stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $8.92, for a total transaction of $178,400.00. Following the completion of the sale, the director now directly owns 74,440 shares in the company, valued at approximately $664,004.80. The trade was a 21.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 250,080 shares of company stock worth $2,194,582 in the last ninety days. Company insiders own 4.80% of the company's stock.

Institutional Trading of Verona Pharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new stake in shares of Verona Pharma in the fourth quarter worth $720,000. Shilanski & Associates Inc. purchased a new stake in shares of Verona Pharma in the 4th quarter valued at about $305,000. Values First Advisors Inc. boosted its position in shares of Verona Pharma by 36.9% during the 4th quarter. Values First Advisors Inc. now owns 23,505 shares of the company's stock valued at $1,092,000 after acquiring an additional 6,331 shares during the last quarter. Choreo LLC bought a new position in shares of Verona Pharma in the fourth quarter worth approximately $230,000. Finally, Legato Capital Management LLC raised its stake in Verona Pharma by 132.9% in the fourth quarter. Legato Capital Management LLC now owns 24,853 shares of the company's stock valued at $1,154,000 after purchasing an additional 14,183 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.